TABLE 1.
Characteristics of blaVIM-harboring A. faecalis strains
| Isolate | Patient type | Source | Resistance genes | MIC (μg/ml)a |
||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IPM | MEM | CTX | CAZ | FEP | ATM | TIC/CLA | SXT | GEN | AMK | TOB | CIP | LEV | DOX | TGC | CST | PMB | ||||
| GZAF1 | Outpatient | Wound | blaVIM-4, aadB, sul1 | 4 | >8 | >32 | >16 | >16 | >16 | 128/2 | >4/76 | >8 | 8 | >8 | ≥4 | >8 | 8 | 1 | 4 | 4 |
| GZAF2 | Inpatient | Wound | blaVIM-4, sul1 | 4 | 2 | >32 | >16 | >16 | 16 | >128/2 | >4/76 | 2 | ≤4 | ≤1 | ≥4 | 4 | ≤2 | 0.5 | 2 | 2 |
| GZAF3 | Outpatient | Urine | aadB, blaVIM-2, sul1, aacA4, dfrB5, dfrA34 | 8 | 2 | >32 | >16 | >16 | 16 | >128/2 | >4/76 | >8 | 32 | >8 | ≥4 | 2 | ≤2 | 0.5 | 2 | 2 |
| GZAF4 | Inpatient | Wound | aadB, blaVIM-2, sul1, aacA4, dfrB5, dfrA34 | 8 | 2 | >32 | >16 | >16 | >16 | 128/2 | >4/76 | >8 | ≤4 | >8 | ≥4 | >8 | 4 | 1 | 4 | 2 |
| GZAF5 | Inpatient | Wound | aadB, blaVIM-2, sul1, aacA4, dfrB5, dfrA34 | 4 | ≤1 | >32 | >16 | >16 | >16 | 128/2 | >4/76 | >8 | ≤4 | >8 | ≥4 | >8 | 4 | 2 | 2 | 2 |
a
MICs were determined using broth microdilution. IPM, imipenem; MEM, meropenem; CAZ, ceftazidime; CTX, cefotaxime; FEP, cefepime; ATM, aztreonam; TIC/CLA, ticarcillin-clavulanate; AMK, amikacin; GEN, gentamicin; TOB, tobramycin; DOX, doxycycline; CIP, ciprofloxacin; LVX, levofloxacin; SXT, trimethoprim-sulfamethoxazole; TGC, tigecycline; CST, colistin; and PMB, polymyxin B.